Author name: Leonardo Arias

As a Jan. 1 deadline looms for payers to adopt new prior authorization tech, Epic’s Vice President of Value-Based Care Ryan Bohochik breaks down the industry’s progress so far.

Cuts to federal programs and the loss of enhanced subsidies on the exchanges could deepen an existing healthcare affordability crisis, according to a new report from the Commonwealth Fund.

At AdvaMed’s The MedTech Conference, CEOs from top medical device companies shared how they navigate difficult times, inflation and new technologies.

When used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo in a first-line maintenance setting—a potentially “practice-changing” outcome, according to Truist Securities.

After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized mRNA cancer vaccine data that last week spurred a stock selloff for both partners.

While biopharma financing exit activity has remained strong through the third quarter, public-market performance for the same period was muted, with most of the yearly gains for the U.S. biotech-specific index largely driven by the first half of 2026.

JNJ-6143, which came from Johnson & Johnson’s $3 billion takeover of Halda Therapeutics in 2025, showed a 75% overall response rate in the Phase 1 readout.

Extending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.

Durante décadas, la endocrinología y la neurología caminaron por senderos separados. La ciencia comprendía que el cerebro dirigía los pensamientos y los nervios, mientras que las glándulas endocrinas —como la tiroides, las suprarrenales o los ovarios&m …

Cuando encendemos una cerilla, mezclamos ácido con bicarbonato o observamos cómo se oxida un clavo de hierro, somos testigos de una transformación milagrosa. Vemos los reactivos (los ingredientes iniciales) convertirse en productos (el resultado final). Sin embargo, entre el ant …